Agensys, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1997-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.agensys.com
Clinical Trials
3
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Phase 1
Completed
- Conditions
- Carcinoma, Renal CellRenal Cell Carcinoma of Papillary HistologyRenal Cell Carcinoma With Clear Cell HistologyRenal Cell Carcinoma With Non-Clear Cell Histology
- Interventions
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Agensys, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT01672775
- Locations
- 🇺🇸
Site US00005 University of Michigan Medical Center, Ann Arbor, Michigan, United States
🇺🇸Site US00003 Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Site US00004 Roswell Park Cancer Institute, Buffalo, New York, United States
A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002
Phase 2
Completed
- Conditions
- Pancreatic CancerCarcinoma, Pancreatic DuctalPancreatic Disease
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Agensys, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT01608711
- Locations
- 🇺🇸
Site US116, Madison, Wisconsin, United States
🇨🇦Site CA00203, Toronto, Canada
News
No news found